PCSK9 remains an important target in cholesterol research. One of the hurdles in this research area is determining which PSCK9 form is present and binding with LDLR. Our new Human PCSK9 Functional Assay Kit is designed to detect active PSCK9 binding with LDLR.
Briefly, PCSK9 binds to LDLR (which is located on the membrane) and marks it for recycling, thereby resulting in fewer LDLR receptors available to collect and internalize circulating LDL. This can lead to hypercholesterolemia in some individuals. It has been observed that when PCSK9 is inhibited, plasma LDL-cholesterol is also lowered. For this reason, doctors and pharmaceutical companies are interested in this metabolism target. We have a couple previous blog posts to refresh your memory.
When PCSK9 is synthesized, it is inactive. Proprotein convertases remove the activity blocking peptide chain, resulting in PCSK9 activation. PCSK9 can be present in different forms- active, non-active, or a mutated state. So how do you know if PCSK9 is actually binding to LDLR? Which form is binding? Can you add an inhibitor and be able to measure this binding? Our new PCSK9 functional assay ELISA kit will help you! This kit is primarily designed for the semi-quantitative in vitro measurement of functionally active PCSK9 in serum and plasma, which is capable of binding to LDL receptor (LDLR). The assay system of #CY-8153 detects the binding between LDLR and active PCSK9. Recombinant LDLR is immobilized in the wells, and allows for the binding of functional PCSK9. Anti-PSCK9 antibodies are then used to detect binding.
We offer various PCSK9 kits. Discover your perfect kit below:
